Live Webinar: Cutting-Edge Applications of AI in Drug Formulation and Polymorph Research

Artificial intelligence is profoundly reshaping the landscape of drug development by enhancing efficiency and breaking through traditional success rate bottlenecks, driving a paradigm shift in the pharmaceutical field. As an industry leader, XtalPi recently reached a pipeline collaboration worth HKD 47 billion with DoveTree, setting a new record for AI + robotics-driven drug discovery orders; its incubated company Signet Therapeutics.Through its collaboration with XtalPi in developmentSIGX1094R, the world's first targeted drug for diffuse gastric cancer, has been selected for the Galien Award's "Best Biotechnology Product," known as the "Nobel Prize of the pharmaceutical industry."”；XtalPiThe intelligent autonomous experimentation platform has also been selected for the 2025 World Artificial Intelligence Conference Innovation Achievements Exhibition. These milestone events clearly demonstrate that AI-driven drug discovery has become an irreversible cornerstone of current pharmaceutical research, steering the future direction of the global drug development industry.

Solid Form Research as a Key Step in Small Molecule Drug DevelopmentTraditional methods, which rely on expert experience and extensive experimentation, struggle to balance efficiency with quality. In the current field of solid-state research, especially in crystallography, AI and computational simulations have emerged as important cutting-edge predictive tools. These technologies not only open new avenues for solid-state research but also provide systematic solutions. They can effectively assist in various aspects such as experimental design, result interpretation, polymorph identification, and screening, significantly improving experimental efficiency and research quality. Additionally, in areas like crystal structure prediction, evaluation of key properties (e.g., crystal habit, solubility, and mechanical performance), salt and cocrystal screening, and solvate characterization, artificial intelligence methods can substantially reduce R&D decision-making costs and shorten development timelines.

September 11, PharmCircle and XtalPi jointly invitedDr. Yizu Zhang, Senior Scientist of Solid-State Computing at XtalPi, and Dr. Xiang Liu, Senior Scientist of Solid-State Structure Determination at XtalPiShanghai Xingweida Pharmaceutical Technology Co., Ltd.Dr. Wei Haojuan, Head of Pharmaceutical TechnologyGuesting in an online live broadcast studio, focusing on the core pain points of solid-state and formulation research, this session will analyze the practical applications of AI technology in crystal form screening and formulation design from the perspective of a "computation + experimentation" dual-driven approach. It will provide a technical overview and application analysis of innovative technologies such as MicroED, crystal form prediction, and AI-driven formulation, transforming the traditional trial-and-error model of solid-state and formulation research into an intelligent design model.

Zhang Yizu

Senior Scientist of Solid-State Computing at XtalPi

Graduated from Imperial College London with 6 years of research and practical experience in crystal polymorph prediction. Has conducted in-depth research in intermolecular interactions and hydrate polymorph prediction. Doctoral advisors were Professor Claire S. Adjiman and Professor Constantinos C. Pantelides, Fellows of the Royal Academy of Engineering (UK). Has led or participated in dozens of drug polymorph prediction projects. Possesses a deep understanding of crystal structure analysis and computational methods for solid-state properties of small molecule drugs.

Liu Xiang

Senior Scientist of Solid-State Structure Determination at XtalPi

Graduated from Drexel University in the United States in 2016 with a Ph.D. in Chemistry, focusing on computational chemistry and semiconductor crystal materials research, with extensive experience in chemistry, crystallography, and materials science. Joined XtalPi in 2019, and currently primarily responsible for the development and application of MicroED technology. Has rich experience in applying MicroED technology for solid-state structure determination of small molecule drugs, with particular expertise in structure resolution and refinement as well as method development.

Wei Haojuan

Head of Pharmaceutical Technology at Shanghai Xingweida Pharmaceutical Technology Co., Ltd.

Ph.D. in Chemical Engineering with over 15 years of experience in pharmaceutical process development. Previously responsible for process development, scale-up optimization, technology transfer, process validation, and NDA registration support for multiple late-stage projects at AbbVie in the United States. Later joined STA Pharmaceutical as the head of the Process Engineering Technology platform, promoting team efforts in crystallization process development, API particle size and morphology control, process simulation, PAT, and other platform technology initiatives. Currently serving as the pharmaceutical technology lead at Shanghai Xingweida Pharmaceutical Technology Co., Ltd., dedicated to developing high-quality and efficient platform technologies to provide patients with premium products.